Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study
Shah S, Markatia Z, Watane A, Feldman A, Shah L, Sridhar J. Do published trial results influence physician prescribing patterns? Intravitreal antivascular endothelial growth factor usage by the United States Ophthalmologists before and after Protocol T study. Current Opinion In Ophthalmology 2023, 34: 218-225. PMID: 36866850, DOI: 10.1097/icu.0000000000000944.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsBevacizumabDiabetic RetinopathyEndothelial Growth FactorsHumansIntravitreal InjectionsOphthalmologistsPractice Patterns, Physicians'RanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsReview Literature as TopicUnited StatesVascular Endothelial Growth Factor AVisual AcuityConceptsDiabetic macular edemaClinical trial publicationsAflibercept injectionsTrial publicationsAntivascular endothelial growth factor medicationsTreatment of DMEAnti-VEGF agentsGrowth factor usageMacular edemaVEGF agentsLabel bevacizumabT studyTrial resultsBevacizumabYear of publicationMean proportionAverage numberPhysiciansFactor usageTreatmentInjectionIndicationsYearsAfliberceptMedications